Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled salbutamol for transient tachypnea of the newborn
IRCT20250811066816N1Phase 2Completed
- Sponsor
- Kashan University of Medical Sciences
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of salbutamol in transient tachypnea of the newborn (TTN) (2 arms), sponsored by Kashan University of Medical Sciences. Primary endpoints: Anderson-Silverman respiratory distress score, Respiratory rate per minute and 3 more. Started Sep 2025; status: completed.
02
Drugs
salbutamol
03
Conditions
transient tachypnea of the newborn (TTN)
Beyond the preview
Go deeper on IRCT20250811066816N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250811066816N1.